Agile Therapeutics, Inc. (AGRX) News
Filter AGRX News Items
AGRX News Results
|Loading, please wait...|
AGRX News Highlights
- AGRX's 30 day story count now stands at 3.
- Over the past 23 days, the trend for AGRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- AL are the most mentioned tickers in articles about AGRX.
Latest AGRX News From Around the Web
Below are the latest news stories about AGILE THERAPEUTICS INC that investors may wish to consider to help them evaluate AGRX as an investment opportunity.
Shares of Agile Therapeutics (NASDAQ: AGRX) were up more than 23% for the week as of 3 p.m. on Thursday, according to data provided by S&P Global Market Intelligence. The stock got a boost late last week when it got an upgrade from analysts at Maxim Group with a buy rating and a price target of $5. It also helps that the stock appears to have avoided the threat of being delisted from the Nasdaq for now.
PRINCETON, NJ / ACCESSWIRE / September 28, 2023 / Maxim Group, a major investment bank, conducts and publishes stock analysis through its Equity Research team. The team has a strong reputation in the industry; a host of major firms use its research. ...
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and Chief Commercial Officer Amy Welsh will present at the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY. Details on the Company presentation are as follows: Event: H.C. Wainwright 25th Annual Global Investment Conference Date: Wednesday, Sep
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
On August 9, Agile Therapeutics (NASDAQ:AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, Twirla® (levonorgestrel and ethinyl estradiol), and a widening gross margin thanks to net revenue growth and decreasing operating expenses.
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript August 9, 2023 Agile Therapeutics, Inc. beats earnings expectations. Reported EPS is $-3.1, expectations were $-3.48. Operator: Good morning, and welcome to the Agile Therapeutics Second Quarter of 2023 Financial Results Conference Call. Please note today’s event is being recorded. I would now like to turn […]
Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to First Quarter 2023 Gross Margin Grows to 58% in Second Quarter 2023 from 47% in First Quarter 2023 Company Reaffirms Expected Full Year 2023 Net Revenue in Range of $25-$30 Million Management to Host Conference Call Today, Wednesday, August 9, 2023 at 8:30 a.m. ET PRINCETON, N.J., Aug. 09, 2023 (GLOB
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Live Conference Call and Webcast at 8:30 a.m. ETPRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before the market open on Wednesday, August 9, 2023. Following the release, the Company will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results and provide a business update. EventAgile Therapeutics Second Quarter
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys
Agile Therapeutics, Inc.'s(NASDAQ:AGRX) partnership with Afaxys Pharma is expected to play a key role in propelling the women's healthcare company toward its $25-$30 million net annual revenue target for 2023.
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
This month, Agile Therapeutics, Inc. (NASDAQ:AGRX) announced partnerships with FPA Women's Health and vitaCare Prescription Services that will expand access to Twirla® (levonorgestrel and ethinyl estradiol) transdermal system, its low-dose weekly birth control patch.
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden’s Latest Executive Order Expanding Contraceptive Coverage
- In June, President Biden issued an Executive Order on Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services. It directs the Secretaries of Health and Human Services (HHS), Labor and the Treasury to issue new guidance that ensures all contraceptives approved by the Food and Drug Administration (FDA) are covered without cost-sharing by private health insurance.